UAE approves expanded Sanofi diabetes therapy for younger patients

UAE health authorities have approved expanded indications for Sanofi’s immunomodulatory therapy in type 1 diabetes, opening access for children as young as 1 and expanding use in recently diagnosed pediatric patients ages 8 to 17. The move could push care toward earlier disease interception, rather than only managing symptoms after diagnosis.

Why it matters: - The approval expands proactive treatment options for type 1 diabetes, a complex autoimmune disease that affects children, adolescents and adults. - The therapy can now be used to delay the onset of Stage 3 type 1 diabetes in children as young as 1. - The decision also allows use in pediatric patients ages 8 to 17 who have recently been diagnosed with Stage 3, with the goal of delaying the decline in endogenous insulin production. - The change moves care toward earlier intervention in the autoimmune process, while insulin remains essential for people living with type 1 diabetes.

What happened: - UAE health authorities approved expanded indications for Sanofi’s immunomodulatory therapy in type 1 diabetes on July 15, 2026. - Sanofi said the accelerated approval marks a milestone in the evolution of care in the UAE. - The approval reinforces the UAE’s position as a healthcare hub in the Middle East, according to the company.

The details: - The therapy is now approved to delay the onset of Stage 3 type 1 diabetes in children as young as 1 year old. - The therapy is also approved to delay the decline in endogenous insulin production in pediatric patients ages 8 to 17 who were recently diagnosed with Stage 3 type 1 diabetes. - Sanofi described the treatment as a disease-modifying therapy that shifts care from reactive symptom management to active disease interception. - Lama Saleh, General Manager Greater Gulf, General Medicines at Sanofi, said the milestone reflects the UAE’s commitment to bringing scientific progress closer to patients and families. - Saleh said Sanofi aims to work with the healthcare community to establish a proactive standard of care that anticipates disease, protects beta cell function and improves quality of life. - The company said the UAE’s medical infrastructure supports faster adoption of proactive disease management.

Between the lines: - The approval signals a broader shift in type 1 diabetes care from treating blood sugar symptoms after diagnosis to trying to slow the disease before it fully progresses. - The update also suggests the UAE is positioning itself as an early adopter of new diabetes therapies and care models. - Sanofi is framing the decision as one of the most important advances in type 1 diabetes care since insulin, which underscores how central this approval is to the company’s message.

What's next: - The expanded indication should make the therapy available earlier in the disease course for more children and teens in the UAE. - Sanofi is expected to continue working with local healthcare providers to integrate the treatment into proactive diabetes care pathways. - The approval may influence how other markets evaluate earlier intervention in type 1 diabetes.